

# Sarecycline Demonstrated Reduced Activity Against Representative Bacterial and Fungal Microflora Commonly Present in the Human Gastrointestinal Tract

Mahmoud A. Ghannoum<sup>1,2</sup>, Janet Herrada<sup>1</sup>, Ahmed Gamal<sup>1,2</sup>, Lisa Long<sup>1,2</sup>, Thomas S. McCormick<sup>2</sup>, and Ayman Grada<sup>3</sup>  
<sup>1</sup>University Hospital Cleveland Medical Center, Center for Medical Mycology, <sup>2</sup>Case Western Reserve University, Department of Dermatology and <sup>3</sup>R&D and Medical Affairs, Almirall US, Malvern, PA, USA  
<sup>\*</sup>Corresponding author: Mahmoud Ghannoum, PhD, MBA, FAAM, FIDSA



## Objective

Evaluate the effect of sarecycline, a narrow spectrum antibiotic, compared to minocycline, a broad-spectrum antibiotic, against a panel of microorganisms that reflect the diversity of the gut microbiome using *in vitro* minimum inhibitory concentration (MIC) testing and time-kill kinetic assays.

## Methods

### 1. Chose representative bacterial and fungal strains found in the Healthy Gut



### 2. Perform Antimicrobial Susceptibility Testing

Minimum inhibitory concentration (MIC) testing was performed using modified Clinical Laboratory Standards Institute methodology



### 3. Establish Growth Curves

*E. coli* and *Candida tropicalis* were selected as representative of aerobic bacteria and yeast, respectively. While *Lactobacillus paracasei* and *Bifidobacterium adolescentis* were selected as representative of anaerobic bacteria that colonize the gut.

Table 1. Susceptibility Testing Results for sarecycline and minocycline Against Healthy Gut Microbes (µg/mL, n=28)



Phylum	Genus	Species	Sarecycline	Minocycline	Fold Difference in MIC
Actinobacteria	<i>Bifidobacterium</i>	<i>Bifidobacterium adolescentis</i>	1	1	1
Actinobacteria	<i>Collinsella</i>	<i>Collinsella aerofaciens</i>	1	0.5	2
Actinobacteria	<i>Eggerthella</i>	<i>Eggerthella lenta</i>	1	0.5	2
Actinobacteria	<i>Actinomycetales</i>	<i>Propionibacterium freudenreichii</i>	8	1	8
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides caccae</i>	8	0.25	32
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides fragilis enterotoxigenic (ET)</i>	2	4	0.5
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides fragilis nontoxigenic</i>	1	0.25	4
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides ovatus</i>	0.5	0.5	1
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides thetaiotaomicron</i>	0.25	0.125	2
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides uniformis</i>	2	0.5	4
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides vulgatus</i>	0.125	0.016	7.8
Bacteroidetes	<i>Bacteroides</i>	<i>Bacteroides xylosoxydans</i>	1	0.25	4
Bacteroidetes	<i>Bacteroides</i>	<i>Bifidobacterium subtilis Biavati</i>	>8	8	Not Determined
Bacteroidetes	<i>Odoribacter</i>	<i>Odoribacter splanchnicus</i>	8	4	2
Bacteroidetes	<i>Parabacteroides</i>	<i>Parabacteroides distans</i>	8	2	4
Bacteroidetes	<i>Parabacteroides</i>	<i>Parabacteroides merdae</i>	0.06	0.016	3.8
Firmicutes	<i>Blautia</i>	<i>Blautia obeum</i>	1	0.5	2
Firmicutes	<i>Clostridium</i>	<i>Clostridium bolteae</i>	4	0.5	8
Firmicutes	<i>Clostridium</i>	<i>Clostridium ramosum</i>	2	0.06	33.3
Firmicutes	<i>Clostridium</i>	<i>Clostridium saccharolyticum</i>	2	2	1
Firmicutes	<i>Dorea</i>	<i>Dorea formicigenerans</i>	0.25	0.06	4.2
Firmicutes	<i>Eubacterium</i>	<i>Eubacterium eligens</i>	>8	4	Not Determined
Firmicutes	<i>Lactobacillus</i>	<i>Lactobacillus paracasei</i>	1	0.25	4
Proteobacteria	<i>Escherichia</i>	<i>Escherichia coli IAH</i>	16	8	2
Sac fungi	<i>Candida</i>	<i>Candida albicans</i>	32	16	2
Sac fungi	<i>Candida</i>	<i>Candida glabrata</i>	32	32	1
Sac fungi	<i>Candida</i>	<i>Candida parapsilosis</i>	32	16	2
Sac fungi	<i>Candida</i>	<i>Candida tropicalis</i>	16	16	1

Higher fold difference indicates lower sarecycline activity

Compared to minocycline, sarecycline showed significantly less antimicrobial activity against:



- 10 of 12 isolates from the *Bacteroidetes* phylum
- 3 out of 4 isolates from *Actinobacteria* phylum
- 5 of 7 isolates from the *Firmicutes* phylum, *E. coli*
- *Propionibacterium freudenreichii* (≥ 3 dilutions)
- Sarecycline also showed less activity against 2 *Candida* species

Figure 1. and 2. Effect of sarecycline vs. minocycline on the growth rates of Aerobic Microorganisms



- Sarecycline showed significantly less activity against *E. coli* compared to minocycline at all time points (P-values <0.05)
- Sarecycline was significantly less active against *C. tropicalis* compared to minocycline at 20 and 22 hours post exposure (P-values <0.05)
- Time kill study shows that with longer time exposure sarecycline has less inhibitory activity against *Candida*

Figure 3. and 4. Effect of sarecycline vs. minocycline on the growth rates of Anaerobic Microorganisms



- Sarecycline showed significantly less activity against *L. paracasei* compared to minocycline after 24 hours of growth (P-value of 0.002)
- Sarecycline showed significantly less activity against *B. adolescentis* compared to minocycline after 48 hours of growth (P-value of 0.042)

- In this study, sarecycline demonstrated less activity against 79% of the microorganisms normally found in a healthy human gut, when compared to minocycline
- Sarecycline is a narrow-spectrum antibiotic
- Our data suggests that sarecycline may have less impact on disrupting commensal and symbiotic organisms residing in the gut and is less likely to promote dysbiosis. *In vivo* evaluation is ongoing